243 related articles for article (PubMed ID: 32317514)
1. Dual-color dual-hapten in situ hybridization (D-DISH) - Comparison with fluorescence in situ hybridization (FISH) for HER2/neu testing in breast cancer.
Gajaria PK; Tambe S; Pai T; Patil A; Desai SB; Shet TM
Indian J Pathol Microbiol; 2020; 63(2):194-199. PubMed ID: 32317514
[TBL] [Abstract][Full Text] [Related]
2. Validation of Dual-Color Dual In Situ Hybridization for HER2/neu Gene in Breast Cancer.
Rathi A; Sahay A; Shet TM; Patil A; Desai SB
Arch Pathol Lab Med; 2024 Apr; 148(4):453-460. PubMed ID: 37490416
[TBL] [Abstract][Full Text] [Related]
3. [Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization].
Xu Y; Yang W; Yang F; Lu Y; Cai X; Zhou X
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):226-30. PubMed ID: 24915811
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Dual-ISH (DISH) With Fluorescence In Situ Hybridization (FISH) and Correlation With Immunohistochemical Findings for HER2/Neu Status in Breast Carcinoma.
Layfield LJ; Wallander ML; Tripp SR; Redpath S; Banks PM
Appl Immunohistochem Mol Morphol; 2017 Apr; 25(4):231-236. PubMed ID: 26766122
[TBL] [Abstract][Full Text] [Related]
5. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
Lim SJ; Cantillep A; Carpenter PM
Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
[TBL] [Abstract][Full Text] [Related]
6. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
[TBL] [Abstract][Full Text] [Related]
7. Comparison of HER2 Dual-Color and Fluorescence In Situ Hybridization in Breast Cancer: A Cohort Study Emphasizing Equivocal Cases.
Shao T; Wood M; Wing A; Hnatovska M; Mendes M; Brendan Mullen J; Chang MC
Am J Clin Pathol; 2016 Sep; 146(3):339-45. PubMed ID: 27543979
[TBL] [Abstract][Full Text] [Related]
8. Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases.
Gao FF; Dabbs DJ; Cooper KL; Bhargava R
Am J Clin Pathol; 2014 Jan; 141(1):102-10. PubMed ID: 24343743
[TBL] [Abstract][Full Text] [Related]
9. Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer.
Horii R; Matsuura M; Iwase T; Ito Y; Akiyama F
Breast Cancer; 2014 Sep; 21(5):598-604. PubMed ID: 23307494
[TBL] [Abstract][Full Text] [Related]
10. Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer.
Mansfield AS; Sukov WR; Eckel-Passow JE; Sakai Y; Walsh FJ; Lonzo M; Wiktor AE; Dogan A; Jenkins RB
Am J Clin Pathol; 2013 Feb; 139(2):144-50. PubMed ID: 23355198
[TBL] [Abstract][Full Text] [Related]
11. Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections.
Nishimura R; Okamoto N; Satou M; Kojima K; Tanaka S; Yamashita N
Breast Cancer; 2016 Nov; 23(6):917-921. PubMed ID: 26746842
[TBL] [Abstract][Full Text] [Related]
12. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists.
Dietel M; Ellis IO; Höfler H; Kreipe H; Moch H; Dankof A; Kölble K; Kristiansen G
Virchows Arch; 2007 Jul; 451(1):19-25. PubMed ID: 17562074
[TBL] [Abstract][Full Text] [Related]
13. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
14. Comparison of dual-color dual-hapten brightfield in situ hybridization (DDISH) and fluorescence in situ hybridization in breast cancer HER2 assessment.
Kosa C; Kardos L; Kovacs J; Szollosi Z
Pathol Res Pract; 2013 Mar; 209(3):147-50. PubMed ID: 23419693
[TBL] [Abstract][Full Text] [Related]
15. Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization.
Solomon JP; Dell'Aquila M; Fadare O; Hasteh F
Am J Clin Pathol; 2017 Apr; 147(4):432-437. PubMed ID: 28340220
[TBL] [Abstract][Full Text] [Related]
16. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
Ni R; Mulligan AM; Have C; O'Malley FP
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
[TBL] [Abstract][Full Text] [Related]
17. Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.
Hartman AK; Gorman BK; Chakraborty S; Mody DR; Schwartz MR
Arch Pathol Lab Med; 2014 Apr; 138(4):553-8. PubMed ID: 24678687
[TBL] [Abstract][Full Text] [Related]
18. HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens.
Nishimura R; Okamoto N; Satou M; Kojima K; Tanaka S
Diagn Cytopathol; 2016 Apr; 44(4):274-9. PubMed ID: 26800514
[TBL] [Abstract][Full Text] [Related]
19. HER2 assessment by bright-field dual in situ hybridization in cell blocks of recurrent and metastatic breast carcinoma.
Edelweiss M; Sebastiao APM; Oen H; Kracun M; Serrette R; Ross DS
Cancer Cytopathol; 2019 Nov; 127(11):684-690. PubMed ID: 31544361
[TBL] [Abstract][Full Text] [Related]
20. [Comparison between analysis of HER2 gene and chromosome 17 in breast cancer by dual-probe chromogenic in situ hybridization and fluorescence in situ hybridization].
Bai YF; Ren GP; Wang B; Teng LS; Liu X
Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):161-5. PubMed ID: 20450761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
